FROM OUR BLOG

Mortgage Rates Top 7%; Fed Hedge Bets Rise | Practice Deals

US mortgage rates hit a two-year high above 7%, traders hedge Fed bets, and earnings upgrades stall. Plus: top healthcare practice business news.

September 23, 2026

Healthcare Practice & Business Deals

20110420-RD-LSC-0350
“20110420-RD-LSC-0350” — public domain (source)

No qualifying small-to-medium practice sale or acquisition appeared in this week’s healthcare feeds. The candidate stories cover AI funding rounds, regulatory policy, workforce surveys, and large health-system activity — none of which meets the specific named-deal criteria for this section. Watch for deal flow to resume in next week’s edition.

Global Markets & Macro

Placeholder
“Placeholder”, by ehnmark, licensed under BY 2.0, via source

Several major macro forces are converging this week, from surging mortgage costs to shifting Fed expectations and a breakdown in the US earnings upgrade cycle.

Mortgage rates breach 7%. US mortgage rates climbed above 7% for the first time in more than two years. The move adds further pressure to a housing market already struggling with elevated prices and sluggish sales. Higher borrowing costs are now weighing on both buyers and sellers, deepening an affordability crisis that shows little sign of easing.

Traders hedge against a shallower Fed cycle. Options markets show traders actively loading up on hedges against the possibility that the Federal Reserve raises rates by less than currently priced. Meanwhile, equity analysts have turned net negative on the US earnings outlook for the first time in months. That breaks the longest run of earnings upgrades in five years. Concerns about inflation and higher interest rates are driving the reversal.

OECD warns on bond yields and public finances. The OECD sounded an alarm over surging government bond yields globally. The Paris-based forecaster says rising debt interest bills are increasing pressure on public finances across major economies. Separately, the OECD said the Bank of England does not need to raise interest rates, arguing the UK is starting from a different position than other countries on monetary policy.

Stocks and the dollar in focus. US stock futures slipped in recent sessions as crude oil ended its longest losing streak of the year. The dollar hit its highest level since July. Traders remain cautious as they wait for further developments in efforts to end the US-Iran conflict, which continues to disrupt energy supply chains — including cooking gas supply from the Persian Gulf to major importers such as India.

Trump-Xi meeting shapes geopolitical mood. Chinese President Xi Jinping is set to arrive in Washington for a high-stakes meeting with President Trump. Markets are watching closely. Investors see the meeting as a potential signal on whether the US-China trade détente will hold or fracture, with significant implications for global supply chains and risk sentiment.

Private equity in limbo. The Financial Times reports that private equity’s growth model — built on a clear bargain with investors — is under strain. Exit markets remain challenging and the fundraising environment is difficult. That dynamic is playing out in individual deals too: Lone Star Funds is weighing options for Italian coffee machine maker Evoca, including a potential handover to creditors, underscoring the stress facing leveraged buyouts in a high-rate environment.

What to Watch

The week ahead centers on two pressure points. In markets, traders will scrutinize any Fed communication for clues on the rate path, especially as mortgage costs above 7% begin to ripple through the broader economy and the earnings upgrade cycle cracks. In healthcare, practice owners and buyers should monitor how rising borrowing costs affect deal financing — higher rates compress valuations and can slow transaction timelines. The Trump-Xi summit adds a wildcard: any shift in trade policy could affect supply chains, staffing costs, and equipment prices for practice operators across the country.


Editorial note, image use & corrections. This report is compiled and summarized from publicly available news sources; figures and details should be independently verified. Accompanying images are used under Creative Commons or public-domain licenses (sourced via Openverse) and credited where required. If you believe any content — written or image — has been used in error, is inaccurate, or infringes your rights, or you wish to request a correction or removal, please contact us at info@tenetma.com and we will address it promptly.

THINKING ABOUT SELLING YOUR MEDICAL PRACTICE?

Get a confidential practice valuation.

If you’re considering selling your practice — or exploring your options — a confidential valuation is a helpful first step. Understanding market conditions and potential value provides clarity and supports better decisions around timing and strategy.

START THE CONVERSATION

If you’re considering a sale, exploring acquisitions or planning ahead,
we’re here to help.

Schedule a confidential consultation to learn how our services can support your goals.